# with previously treated, unresectable or metastatic HER2-positive FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/with-previously-treated-unresectable-or-metastatic-her2-positive

> No upcoming FDA catalysts in with previously treated, unresectable or metastatic HER2-positive; 2 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 20, 2024 | [Ziihera® (zanidatamab) FDA approval](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | with previously treated, unresectable or metastatic HER2-positive | completed, approved | "On November 20, 2024, Jazz Pharmaceuticals plc (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") accelerated approval of Ziihera®(zanidatamab-hrii) 50mg/mL for injection for IV for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1232524/000119312524262940/d832756d8k.htm)) |
| February 25, 2025 | [Ziihera® (zanidatamab) FDA approval](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | with previously treated, unresectable or metastatic HER2-positive | completed, approved | "•In 4Q24, announced U.S. FDA granted accelerated approval of Ziihera (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252425000009/a4q24financialpr.htm)) |

## Drugs

- [Ziihera® (zanidatamab)](https://sec-api.dev/pdufa/zanidatamab) (JAZZ)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/with-previously-treated-unresectable-or-metastatic-her2-positive.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "with previously treated, unresectable or metastatic HER2-positive FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/with-previously-treated-unresectable-or-metastatic-her2-positive

```bibtex
@misc{secapidev_indications_with_previously_treated_unresectable_or_metastatic_her2_positive_20261116,
  title        = {with previously treated, unresectable or metastatic HER2-positive FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/with-previously-treated-unresectable-or-metastatic-her2-positive}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_with_previously_treated_unresectable_or_metastatic_her2_positive_20261116","title":"with previously treated, unresectable or metastatic HER2-positive FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/with-previously-treated-unresectable-or-metastatic-her2-positive","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
